California's Quidel picked up FDA clearances for two infectious disease tests that run on Life Technologies' diagnostics platform, and the two companies are partnering up to spread the assays around the globe.
Theorem Clinical Research has struck a deal with Charles River Laboratories, adding the early-phase-focused CRO's capabilities to its drug development platform.
In the ongoing hunt to uncover new therapies for rare diseases, the NIH has selected four new preclinical drug development studies to support, the findings of which will be shared with other researchers.
Bayer has again reached out to DKSH to expand its presence in Asia, this time tasking the Swiss company with helping it push its therapies in Singapore.
India's TCG Lifesciences has signed up to handle early phase work for Debiopharm's drug-resistant bacteria program, helping the Swiss drug developer as it chases a share of the antibiotics market.
Novartis has picked up its option on a Phase II-ready therapy for a pair of rare disease from Sweden's Camarus, forking over a milestone included in their $700 million pact inked two years ago.
Biogen Idec has added another biotech alliance in neurology. Amicus Therapeutics revealed Tuesday that the biotech giant has agreed to fully fund research and development of the company's Parkinson's disease program.
Biogen Idec and Amicus Therapeutics have struck a deal to hunt for novel small molecules to treat Parkinson's disease. The collaboration will focus on finding small molecules that target the lysosomal enzyme glucocerobrosidase (GCase).
The deal puts Roche--a leader in oncology and a top contender in the immunotherapy field--in the driver's seat on two preclinical therapies that could help marshal a targeted T-cell attack on cancer.
Even the smallest biotech company can benefit when it thinks and acts globally. And a biotech startup that was able to grab a promising therapeutic asset from Pfizer as it shuttered much of its work in the U.K. has pieced together a global virtual organization that illustrates just how effective that can be.